Trump’s pharma tariff proposals: Which stocks face the biggest risk?
Trump's plan to impose steep tariffs on imported generic drugs has caused worry for Indian pharmaceutical companies heavily reliant on US market. Aurobindo Pharma is most at risk, while Torrent Pharma has the least exposure. Sun Pharma's mix of generic and branded products makes it less vulnerable. However, Macquarie believes the proposal is unfeasible and could have negative consequences.